Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Comparison of the broth microdilution methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for testing itraconazole, posaconazole, and voriconazole against Aspergillus isolates.

Literature DB >> 21209166

Comparison of the broth microdilution methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for testing itraconazole, posaconazole, and voriconazole against Aspergillus isolates.

M Pfaller¹, L Boyken, R Hollis, J Kroeger, S Messer, S Tendolkar, D Diekema.

Abstract

We compared EUCAST and CLSI antifungal susceptibility testing methods for itraconazole, posaconazole, and voriconazole by testing 245 Aspergillus clinical isolates. The essential agreement (EA) between methods was excellent: 100% (itraconazole), 98.4% (posaconazole), and 99.6% (voriconazole) assessing EA at ±2 dilutions and 99.6% (itraconazole), 87.7% (posaconazole), and 96.3% (voriconazole) at ±1 dilution.

Entities: Chemical

Mesh：

Substances：

Year: 2011 PMID： 21209166 PMCID： PMC3067683 DOI： 10.1128/JCM.02432-10

Source DB: PubMed Journal: J Clin Microbiol ISSN： 0095-1137 Impact factor: 5.948

25 in total

1. Multiple-triazole-resistant aspergillosis.

Authors: Paul E Verweij; Emilia Mellado; Willem J G Melchers
Journal: N Engl J Med Date: 2007-04-05 Impact factor: 91.245

2. Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST).

Authors: M Cuenca-Estrella; M C Arendrup; E Chryssanthou; E Dannaoui; C Lass-Florl; P Sandven; A Velegraki; J L Rodriguez-Tudela
Journal: Clin Microbiol Infect Date: 2007-08-13 Impact factor: 8.067

3. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors: Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal: Clin Infect Dis Date: 2008-02-01 Impact factor: 9.079

4. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values.

Authors: M A Pfaller; A Espinel-Ingroff; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal: J Clin Microbiol Date: 2011-01-12 Impact factor: 5.948

5. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.

Authors: A Espinel-Ingroff; F Barchiesi; M Cuenca-Estrella; M A Pfaller; M Rinaldi; J L Rodriguez-Tudela; P E Verweij
Journal: J Clin Microbiol Date: 2005-08 Impact factor: 5.948

6. Comparison of the EUCAST-AFST broth dilution method with the CLSI reference broth dilution method (M38-A) for susceptibility testing of posaconazole and voriconazole against Aspergillus spp.

Authors: E Chryssanthou; M Cuenca-Estrella
Journal: Clin Microbiol Infect Date: 2006-09 Impact factor: 8.067

7. Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2).

Authors: Juan Luis Rodriguez-Tudela; J Peter Donnelly; Michael A Pfaller; Erja Chryssantou; Peter Warn; David W Denning; Ana Espinel-Ingroff; Francesco Barchiesi; Manuel Cuenca-Estrella
Journal: J Clin Microbiol Date: 2006-11-08 Impact factor: 5.948

Review 8. Emerging azole antifungals.

Authors: Anne Chen; Jack D Sobel
Journal: Expert Opin Emerg Drugs Date: 2005-02 Impact factor: 4.191

9. In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp.

Authors: Alicia Gomez-Lopez; Guillermo Garcia-Effron; Emilia Mellado; Araceli Monzon; Juan L Rodriguez-Tudela; Manuel Cuenca-Estrella
Journal: Antimicrob Agents Chemother Date: 2003-10 Impact factor: 5.191

10. Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species.

Authors: Erja Chryssanthou; Manuel Cuenca-Estrella
Journal: J Clin Microbiol Date: 2002-10 Impact factor: 5.948

13 in total

Review 1. Antifungal drug discovery: the process and outcomes.

Authors: Richard Calderone; Nuo Sun; Francoise Gay-Andrieu; William Groutas; Pathum Weerawarna; Sridhar Prasad; Deepu Alex; Dongmei Li
Journal: Future Microbiol Date: 2014 Impact factor: 3.165

2. Comparison of the EUCAST and CLSI Broth Microdilution Methods for Testing Isavuconazole, Posaconazole, and Amphotericin B against Molecularly Identified Mucorales Species.

Authors: Anuradha Chowdhary; Pradeep Kumar Singh; Shallu Kathuria; Ferry Hagen; Jacques F Meis
Journal: Antimicrob Agents Chemother Date: 2015-10-05 Impact factor: 5.191

3. Targeted disruption of nonribosomal peptide synthetase pes3 augments the virulence of Aspergillus fumigatus.

Authors: Karen A O'Hanlon; Timothy Cairns; Deirdre Stack; Markus Schrettl; Elaine M Bignell; Kevin Kavanagh; Sinéad M Miggin; Grainne O'Keeffe; Thomas O Larsen; Sean Doyle
Journal: Infect Immun Date: 2011-07-11 Impact factor: 3.441

4. EUCAST testing of Isavuconazole susceptibility in Aspergillus: comparison of results for Inoculum standardization using Conidium counting versus optical density.

Authors: Maiken Cavling Arendrup; Susan Howard; Cornelia Lass-Flörl; Johan W Mouton; Joseph Meletiadis; Manuel Cuenca-Estrella
Journal: Antimicrob Agents Chemother Date: 2014-08-18 Impact factor: 5.191

5. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods.

Authors: Michael A Pfaller; Frederick Duncanson; Shawn A Messer; Gary J Moet; Ronald N Jones; Mariana Castanheira
Journal: Antimicrob Agents Chemother Date: 2011-08-15 Impact factor: 5.191

6. In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods.

Authors: Michael A Pfaller; Shawn A Messer; Mary R Motyl; Ronald N Jones; Mariana Castanheira
Journal: Antimicrob Agents Chemother Date: 2012-12-10 Impact factor: 5.191

7. Cryptic and rare Aspergillus species in Brazil: prevalence in clinical samples and in vitro susceptibility to triazoles.

Authors: C E Negri; S S Gonçalves; H Xafranski; M D Bergamasco; V R Aquino; P T O Castro; A L Colombo
Journal: J Clin Microbiol Date: 2014-07-30 Impact factor: 5.948